Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes
NCT00020969
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
INDUSTRY
Sponsor class
Conditions
Leukemia
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms
Interventions
DRUG:
arsenic trioxide
Sponsor
CTI BioPharma
Collaborators
[object Object]